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Abstract 
Background: The rate of cardiovascular diseases in developing countries is approximately 60% and it is still 
has an increasing trend. The clinical effectiveness of aspirin in preventing cardiovascular events has been 
well proven. Although aspirin is an effective and inexpensive drug, its consumption is not equally beneficial 
for all patients. Many factors can be affective on the efficacy of antiplatelet drugs such as aspirin. 
Methods: This study was carried out on 260 patients who had stable angina pectoris and coronary artery 
disease was approved by coronary angiography. Based on opium addiction, the patients were divided into 
two groups. Opium addiction was diagnosed base on Diagnostic and Statistical Manual of Mental Disorders, 
fourth edition (DSM-IV) criteria. The mid-stream morning urinary sample were collected for measuring the 
urinary 11-dehydroxy thromboxane B2 level (UTXB2). Urinary level of UTXB2 was considered as an aspirin 
resistance index. 
Findings: The mean age of patients was 57.3 ± 8.9; and 44.6% of them were females. The aspirin resistance 
rate was 41.5%. Significant difference in aspirin resistance was observed between the opium addicts and  
non-addicts. (51.5% vs. 31.5%) (P = 0.001). The effects of confounding variables such as diabetes, 
hypertension, and hyperlipidemia were eliminated by regression logistic multivariable analysis. 
Conclusion: The prevalence of aspirin resistance in patients with stable angina pectoris was 41.5%. The 
prevalence of aspirin resistance in patients with stable angina pectoris who had opium addiction was 
significantly higher them non-addicts. 
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Introduction 
Cardiovascular diseases are one of the leading 
causes of disablement and death in the world. The 
global burden of cardiovascular disease in 
developing countries is over 60% and in.1 Since 
the accumulation of platelets is highly effective on 
causing cardiovascular diseases, the inhibition of 
this phenomenon can play an important role in 
preventing cardiovascular diseases.2 Despite 
recent developments in new platelet medications 
in the past decades, aspirin is still one of the most 
commonly used medication for preventing 
cardiovascular diseases worldwide.3-7 The clinical 
effectiveness of aspirin in preventing 
cardiovascular events has been well proven. 
Aspirin interferes with blood’s clotting action. 
Long-term use of aspirin lowers the risk of  
non-fatal MI by 34%, non-fatal stroke by 25%, and 
death in patients with coronary occlusion.6,7 It 
appears that the antithrombotic potency of aspirin 
for preventing platelet function through blocking 
of Eicosanoids is essential.8 
Despite the fact that aspirin is an effective, 
inexpensive and safe medication, its consumption 
is not equally beneficial for all patients. Many 
modifiable and non-modifiable factors could be 
effective on the efficacy of antiplatelet drugs. A 
proposed mechanism for the limitations of the 
effects of aspirins caused inadequate response to 
aspirin or even resistance to aspirin. Resistance to 
aspirin reduces the preventing effects of aspirin 
against cardiovascular diseases. Some affecting 
factors on aspirin resistance have been reported 
such as side effects of smoking that can lead to 
increased platelet aggregation, the use of non-
steroidal anti-inflammatory drugs, activation of 
the sympathetic nervous system, metabolic 
abnormalities (dyslipidemia, hyperglycemia), 
different methods of platelet activation, diabetes, 
hypertension, the amount and timing of drug use, 
and the genetic alternations of the population.9-16  
According to the results of a survey published 
by Mansour et al., miscellaneous factors 
(including drug interactions, drug, poor 
compliance of patients, anaphylaxis, etc.) clinical 
factors (diabetes, heart failure, coronary 
syndrome, obesity, etc.), and genetic factors can 
cause aspirin resistance.17 
In recent years, much attention was given to 
the changes of platelet suppression in response to 
aspirin in patients. Lack of agreement on a 
standard definition for “aspirin resistance” led to 
reports of different results on the frequency of 
aspirin resistance in different studies. The terms 
“aspirin treatment failure” (used in clinical 
studies), “aspirin non-responsiveness” and 
“aspirin resistance” (used in pharmacological 
studies) have been used in different studies. 
Generally, the patients who despite receiving 
aspirin regularly suffered from cardiovascular 
diseases, or the patients with lab tests indicated 
platelet suppression, may be considered as aspirin 
resistant patients.18 Previous studies reported the 
experimental frequency of the patients with heart 
diseases, which had been studied through 
different methods, as 4% to 83%.9-16 The results of 
a survey on 22 articles, which reviewed the 
aspirin resistance using PFA-100 system, reported 
the frequency of aspirin resistance to 29%.9 
Although it appears that the therapeutic effects of 
aspirin are age and sex independent,5 the study 
conducted by Christiaens et al. indicated that men 
are more aspirin resistant that women.19 
Heart attack is reported the second leading 
cause of death in Kerman, Iran, among other 30 
causes of death (778.9 years of life lost in 100000 
people) which puts this province in the fourth 
place among the other 29 studied provinces, 
regarding the standardized deaths recorded due 
to cardiovascular diseases.20 In s study in Kerman, 
it was estimated that a daily approximation of 37 
people with no heart disease had the history of 
suffering from heart attacks in Kerman, and 5180 
heart attacks happened all over Iran.21 Previously, 
the association between platelet dysfunction in 
methadone users has been investigated,8 but still, 
it is unclear how aspirin affects the major platelet 
receptors in opium-addicted patients with 
coronary artery diseases. 
Due to some incorrect beliefs and myths, 
recommendations to consume opium as to control 
or prevent cardiac diseases, are considered as risk 
factors. Prevalence of opium addiction is different 
in diverse countries, cultures and jobs. Opium is 
the most common substance abuse in Iran. 
Addiction causes great moral and material 
damages and casualties. Very few studies have 
been conducted on the effects of opium addiction 
on body, and the comparison between addicts and 
non-addicts. In this study, the effects of opium 
addiction on aspirin resistance in patients with 
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angina pectoris were investigated. The accepted 
definition of aspirin resistance, which has been 
used in several studies and in the current study is 
“partial (incomplete) suppression of platelet 
aggression assessed through platelet function 
analysis which leads to poor biochemical response 
of platelets to antiplatelet effects of aspirin. 
Methods 
In this study, the outpatients were enrolled in the 
study who were checked in the cardiology clinics 
of the hospitals affiliated to Kerman University of 
Medical Sciences, referred to the cardiologists’ 
private clinics, or the Department of Angiography 
in the second hospital of Kerman University of 
Medical Sciences, and suffered from stable angina 
pectoris and were diagnosed with coronary artery 
diseases through cardiovascular angiography. 
This research was conducted as a case-control 
study. The control group consisted of  
non-addicted patients and the case group 
consisted of patients addicted to opium (patients 
addiction to opium was determined by the 
patients self-reports or according to the criteria of 
Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition (DSM-IV). 
The measurements required for entering into 
the study were, suffering from stable angina 
pectoris, which means, typical cardiac chest pains, 
with a fixed pain severity, time and duration, and 
daily taking of 80-100 ml aspirin regularly for 3 
consecutive months for secondary prevention of 
cardiovascular events. 
The cases opt to withdraw from the study 
were by heart failure, acute coronary syndrome, 
history of coronary-artery bypass graft (CABG) or 
PCI within the past 6 months, major surgeries 
within the past month, having stroke within the 
past 3 months, active abdominal ulcers, chronic 
kidney disease requiring dialysis, severe liver 
diseases, progressive systematic diseases, 
Myeloproliferative disease, history of 
hemorrhagic diseases, clotting disorders, chronic 
infections and inflammation, recent urinary tract 
infections, recent aspirin intolerance, taking 
aspirin and other nonsteroidal anti-inflammatory 
drugs (NSAIDS) simultaneously, Clopidogrel, 
Ticlopidine, Dipyridamole, heparin, enoxaparin, 
warfarin, proton pump inhibitor drugs 
consumption within the past 10 days before 
entering into the study, obesity with body mass 
index (BMI ≥ 30 kg/m2), of consumption, 
consumption of green tea, intake of Omega 3, 
Vitamin C and E. 
Initially, after explaining the objectives and the 
process of the study to the patients and obtaining 
a written consent from the patient or an alternate 
decision-maker, we started the study. Morning 
midstream specimen of urine were collected from 
the patients in a calm mental state, and stored in 
30 °C, until the time to measure the Urinary  
11-dehydroxi Thromboxane B2 (UTXB2) level of 
the samples. Urine drug tests were taken to 
ensure the addiction of the subjects in control 
group. Morning urine specimens were collected 
before angiography, from the patients who were 
admitted to Shafa Hospital. Whereas, the 
angiographic results were positive, the urine 
specimen would enter into the study; otherwise, it 
would be disposed of it. UTXB2 measurement 
was carried out by ELISA, one of the most 
accurate laboratory methods, and due to the 
effects of urine concentration on UTXB2, after 
measuring creatinine levels in urine, UTXB2 level 
in urine was stated based on the creatinine level 
of urine. UTXB2 level in urine was considered as 
an indicator of aspirin resistance7 through UTXB2 
(in pg/ml) × 100 ÷ urine creatinine (mg/dl). 
UTXB2 levels higher than pg/mg 1500 were 
considered as aspirin resistance.  
The researcher collected the patients’ 
demographic information such as age, sex, height, 
weight, history of drugs such as beta blockers, 
statins, ACEI (Angiotensin Converting Enzyme 
Inhibitors), ARB (Angiotensin Receptor Blockers), 
cigarette smoking, DM (Diabetes Mellitus), HTN 
(Hypertension), history of MI (Myocardial 
Infarction) or CABG or PCI (Percutaneous 
Coronary Intervention), CBC (Cellular Blood 
Count) including Hb (Hemoglobin), Platelet 
count, creatinine serum, duration of opium 
addiction, its method of use and amount, the type 
of aspirin consumed (coated or non-coated), the 
duration of taking, and the time aspirin was 
taken, by means of a questionnaire. 
Due to some confounding factors such as 
diabetes, smoking, and blood pressure, that can 
affect aspirin resistance, the information was 
collected from all the subjects, and was taken into 
consideration with statistical analysis. 
 Subsequently, all the data were collected and 
statistically analyzed by SPSS for Windows 
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(version 17, SPSS Inc., Chicago, IL, USA) ,and the 
descriptive analysis of the mean ± standard 
deviation (SD) was used for quantitative data and 
the relative and absolute frequencies were used 
for qualitative data. To compare the acetylsalicylic 
acid (ASA) resistance of both groups, chi-square 
test was used. To eliminate the confounding 
effects of some variables from logistic regression 
test, and to determine the index , and to calculate 
the risks of becoming aspirin resistant in both 
groups of addicts and non-addicts, both crude 
odd ratio (OR) and adjusted odd ratio were used. 
Results 
In this study, 260 subjects have participated, 
which were divided into two groups of case and 
control, 130 people in each, based on their opium 
addiction status, i.e. addicts and non-addicts. The 
general profile of the patients participated in the 
study are presented in table 1. The majority of the 
patients were male (55.4%).  
 
Table 1. General profiles of the participants 
Patients profiles Data 
Age (year) 8.9 ± 57.3 
Sex (female) 116 (44.6%) 
Body mass index (25-30) 108 (41.5%) 
Diabetes mellitus 59 (22.7%) 
Hypertension 88 (33.8%) 
Hyperlipidemia 36 (13.8%) 
Smoking cigarettes 85 (32.7%) 
History of aspirin consumption 85 (32.7%) 
Aspirin resistance 108 (41.5%) 
 
The results of this study indicated that of 260 
patients, 108 cases (41.5%) were aspirin resistant. 
The variables are shown in table 2. The effect of 
confounding variables such as diabetes 
hypertension‚ and hyperlipidemia were 
eliminated by regression logistic multivariable  
analysis in table 3. 
Discussion 
This study was conducted on patients with stable 
angina pectoris to investigate the association 
between opium addiction and aspirin resistance. 
Accordingly, the overall prevalence of aspirin 
resistance in patients with stable angina pectoris in 
Kerman was estimated 41.5%. Various studies in 
diverse populations have estimated the prevalence 
of aspirin resistance (they were studied based on 
the measured parameters and the study subjects), 
between 5.5 to 75.0%.22-25 However, in some 
previous studies, aspirin resistance was not 
observed in normal population and only has been 
reported in patients with cardiovascular diseases, 
diabetes and hypertension.10,26,27 It has been 
articulated in some previous studies that aspirin 
resistance increases the risks of MI, cerebrovascular 
events, and deaths caused by cardiovascular 
events.10,26,27 Christiaens et al. showed that 29.0% of 
the patients with stable angina pectoris were 
aspirin resistant.19 Akay et al. reported aspirin 
resistance in healthy people as 27.0%.28 Singla et al. 
reviewed aspirin resistance in patients with type II 
diabetes and 2.7% were aspirin resistant, and 39.1% 
were relatively resistant to aspirin.29  
Zimmermann and Hohlfeld reported in vitro 
aspirin resistance 60.0%, 70.0% were for stable 
angina pectoris subgroup, 80.0% in MI group, and 
60.0% in stroke and peripheral vascular disease 
group.30 Recent studies in this regard reported the 
resistance causing 70.0% atherosclerotic vascular 
events.12 In the study of Ziaie et al. in Isfahan, Iran, 
the prevalence of aspirin resistance in Isfahan was 
reported 75.3% that was the highest number 
reported among previous studies.25 However, in 
this study, the number was compatible with the 
average aspirin resistance reported in other 
 
Table 2. Study variables in case and control groups 
 Control Case P 
Age (year) 9.2 ± 57.8 8.6 ± 56.8 0.001 
Sex (female) 77 males and 53 females 91 males and 39 females 0.386 
Body mass index (25-30) 56 (43.1%) 52 (40.0%) 0.615 
Diabetes mellitus 23 (17.6%) 36 (27.7%) 0.054 
Hypertension 48 (36.9%) 40(30.8%) 0.294 
Hyperlipidemia 18 (13.8%) 18 (13.8%) 1.000 
Smoking cigarettes 17(13.1%) 40 (30.8%) 0.001 
History of aspirin consumption 43 (33.1%) 42 (32.3%) 0.945 
Aspirin resistance 41 (31.5%) 67 (51.5%) 0.001 
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Table 3. A multivariable logistic regression 
analysis with elimination of confounding factors 
(diabetes, hyperlipidemia, and hypertension) 
 95% CI OR P 
Diabetes 1.50-4.30 2.56 0.001 
Hypertension 0.65-2.35 1.24 0.490 
Hyperlipidemia 1.58-4.82 2.75 0.001 
Opium consumption 0.73-3.49 1.59 0.230 
CI: Confidence interval; OR: Odds ratio 
 
studies. It appears that according to having the 
equivalent sample size and population to other 
studies conducted in this study, the results of this 
study were in the same range as the mean result of 
other studies. The prevalence of aspirin resistance 
also depends upon the experiment procedure and 
this can be an acceptable reason for the difference 
in the result numbers of different studies.25 
According to the results of this study, aspirin 
resistance in addition to hypertension, diabetes, 
and hyperlipidemia can also be caused by 
chronic abuse of opium or addiction to it. In 
studies conducted on aspirin resistance, it was 
shown that any factor that can bind nitric oxide 
(NO) to two molecules of aspirin, leads to the 
formation of NO-aspirin molecule, which does 
not have the properties and efficiencies of aspirin 
molecules anymore.31  
Given the role of opium and opiate substances, 
in oxidizing materials, it causes aspirin resistance 
in patients. The limitations of this study were 
determination of relative and absolute strength of 
the patients in case and control groups, lack of 
information on patients’ aspirin intake dosage 
and consumption and duration before the study, 
and having no accurate information on opium 
intake dosage. 
Conclusion 
In this study, it was shown that the prevalence of 
aspirin resistance in patients with cardiovascular 
diseases was 41.5%, which was in consistent with 
the global rate of the other studies. Aspirin 
resistance in patients addicted to opium was 
higher than patients in control group, and it is 
recommended that the cardiologists and 
cardiology specialty clinics use other platelet 
inhibiting drugs and to avoid prescribing aspirin 
for addicted patients, and also to encourage these 
patients to withdraw more strongly. 
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